CovidSeniorV1, Main, Exploration, bibRecord, 000935

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.

Identifieur interne : 000935 ( Main/Exploration ); précédent : 000934; suivant : 000936

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.

Auteurs : Lu Li [République populaire de Chine] ; Xiaojuan Wang [République populaire de Chine] ; Rongrong Wang [République populaire de Chine] ; Yunzhen Hu [République populaire de Chine] ; Saiping Jiang [République populaire de Chine] ; Xiaoyang Lu [République populaire de Chine]

Source :

Drug design, development and therapy [ 1177-8881 ] ; 2020.

RBID : pubmed:32801640

Descripteurs français

KwdFr :
- Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Antiviraux (pharmacologie), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (isolement et purification), Femelle (MeSH), Grossesse (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Maladie grave (MeSH), Maladies du foie (complications), Maladies du rein (complications), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Sujet âgé (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- effets indésirables : Antiviraux, Maladies du foie, Maladies du rein.
- isolement et purification : Betacoronavirus.
- pharmacocinétique : Antiviraux.
- pharmacologie : Antiviraux.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Femelle, Grossesse, Humains, Maladie grave, Pandémies, Sujet âgé.

English descriptors

KwdEn :
- Aged (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Antiviral Agents (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (isolation & purification), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Critical Illness (MeSH), Female (MeSH), Humans (MeSH), Kidney Diseases (complications), Liver Diseases (complications), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Pregnancy (MeSH).
MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , pharmacokinetics : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- complications : Kidney Diseases, Liver Diseases.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Aged, Critical Illness, Female, Humans, Pandemics, Pregnancy.

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.

DOI: 10.2147/DDDT.S259058
PubMed: 32801640
PubMed Central: PMC7396737

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000621
to stream Main, to step Curation: 000621

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.</title>
<author><name sortKey="Li, Lu" sort="Li, Lu" uniqKey="Li L" first="Lu" last="Li">Lu Li</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Xiaojuan" sort="Wang, Xiaojuan" uniqKey="Wang X" first="Xiaojuan" last="Wang">Xiaojuan Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Rongrong" sort="Wang, Rongrong" uniqKey="Wang R" first="Rongrong" last="Wang">Rongrong Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Hu, Yunzhen" sort="Hu, Yunzhen" uniqKey="Hu Y" first="Yunzhen" last="Hu">Yunzhen Hu</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jiang, Saiping" sort="Jiang, Saiping" uniqKey="Jiang S" first="Saiping" last="Jiang">Saiping Jiang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Lu, Xiaoyang" sort="Lu, Xiaoyang" uniqKey="Lu X" first="Xiaoyang" last="Lu">Xiaoyang Lu</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32801640</idno>
<idno type="pmid">32801640</idno>
<idno type="doi">10.2147/DDDT.S259058</idno>
<idno type="pmc">PMC7396737</idno>
<idno type="wicri:Area/Main/Corpus">000621</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000621</idno>
<idno type="wicri:Area/Main/Curation">000621</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000621</idno>
<idno type="wicri:Area/Main/Exploration">000621</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.</title>
<author><name sortKey="Li, Lu" sort="Li, Lu" uniqKey="Li L" first="Lu" last="Li">Lu Li</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Xiaojuan" sort="Wang, Xiaojuan" uniqKey="Wang X" first="Xiaojuan" last="Wang">Xiaojuan Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Rongrong" sort="Wang, Rongrong" uniqKey="Wang R" first="Rongrong" last="Wang">Rongrong Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Hu, Yunzhen" sort="Hu, Yunzhen" uniqKey="Hu Y" first="Yunzhen" last="Hu">Yunzhen Hu</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jiang, Saiping" sort="Jiang, Saiping" uniqKey="Jiang S" first="Saiping" last="Jiang">Saiping Jiang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Lu, Xiaoyang" sort="Lu, Xiaoyang" uniqKey="Lu X" first="Xiaoyang" last="Lu">Xiaoyang Lu</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Drug design, development and therapy</title>
<idno type="eISSN">1177-8881</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Critical Illness (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Kidney Diseases (complications)</term>
<term>Liver Diseases (complications)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Pregnancy (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacocinétique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (isolement et purification)</term>
<term>Femelle (MeSH)</term>
<term>Grossesse (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Maladie grave (MeSH)</term>
<term>Maladies du foie (complications)</term>
<term>Maladies du rein (complications)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Sujet âgé (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Kidney Diseases</term>
<term>Liver Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Maladies du foie</term>
<term>Maladies du rein</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Critical Illness</term>
<term>Female</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Pregnancy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Grossesse</term>
<term>Humains</term>
<term>Maladie grave</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32801640</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Drug design, development and therapy</Title>
<ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.</ArticleTitle>
<Pagination><MedlinePgn>3001-3013</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S259058</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.</AbstractText>
<CopyrightInformation>© 2020 Li et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<Identifier Source="ORCID">0000-0003-4573-8538</Identifier>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Xiaojuan</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Rongrong</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hu</LastName>
<ForeName>Yunzhen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Saiping</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Xiaoyang</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Drug Des Devel Ther</MedlineTA>
<NlmUniqueID>101475745</NlmUniqueID>
<ISSNLinking>1177-8881</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral therapy</Keyword>
<Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword>
<Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword>
<Keyword MajorTopicYN="N">special population</Keyword>
</KeywordList>
<CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32801640</ArticleId>
<ArticleId IdType="doi">10.2147/DDDT.S259058</ArticleId>
<ArticleId IdType="pii">259058</ArticleId>
<ArticleId IdType="pmc">PMC7396737</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2013 Apr;57(4):1743-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23357765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2010 Dec;36(12):2109-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20862453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Apr;46(4):1123-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11953993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1132-1134</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2019 Jul 25;63(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31109983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Nov;100(2):446-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24084488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Rev. 2013 Jan-Mar;15(1):38-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23449228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2018;23(5):457-461</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29185991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23221983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2020 Jun;26(6):1102-1112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32213260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):105998</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2018 Oct;18(10):1097-1107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30195996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Obstet Gynecol. 2016 Feb;214(2):273.e1-273.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26429521</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2017 Oct;50(4):542-551</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28669839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Sci. 2020 Jun;40(3):480-485</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32474860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):103-112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30582435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 1996 Jan;9(1):42-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8834332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):147-157</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e21-e23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2017 Aug;40:113-118</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28384599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):769-777</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2012 May;91(5):889-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22472986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1991 Feb 9;337(8737):371</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1671273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Feb 19;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2020 Jun 16;52(6):910-941</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32505227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 May 1;248:117477</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32119961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2016 Aug;55(8):907-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26798032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1970 Sep 19;227(5264):1257-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5452818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharmacol. 2006 Mar;46(3):265-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16490802</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Engineering (Beijing). 2020 Mar 18;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ter Arkh. 2017;89(1):62-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28252630</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2016 Apr 21;16:174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27097824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Theor Biol. 2008 Oct 21;254(4):861-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18706430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 1995 Oct;84(10):1210-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8801336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Ophthalmol Med. 2012;2012:182747</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23304587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2001 Sep 8;358(9284):813-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11564493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2016 Jun;72(6):635-649</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26880088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Zhejiang</li>
</region>
<settlement><li>Hangzhou</li>
</settlement>
<orgName><li>Université de Zhejiang</li>
</orgName>
</list>
<tree><country name="République populaire de Chine"><region name="Zhejiang"><name sortKey="Li, Lu" sort="Li, Lu" uniqKey="Li L" first="Lu" last="Li">Lu Li</name>
</region>
<name sortKey="Hu, Yunzhen" sort="Hu, Yunzhen" uniqKey="Hu Y" first="Yunzhen" last="Hu">Yunzhen Hu</name>
<name sortKey="Jiang, Saiping" sort="Jiang, Saiping" uniqKey="Jiang S" first="Saiping" last="Jiang">Saiping Jiang</name>
<name sortKey="Lu, Xiaoyang" sort="Lu, Xiaoyang" uniqKey="Lu X" first="Xiaoyang" last="Lu">Xiaoyang Lu</name>
<name sortKey="Wang, Rongrong" sort="Wang, Rongrong" uniqKey="Wang R" first="Rongrong" last="Wang">Rongrong Wang</name>
<name sortKey="Wang, Xiaojuan" sort="Wang, Xiaojuan" uniqKey="Wang X" first="Xiaojuan" last="Wang">Xiaojuan Wang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000935 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000935 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidSeniorV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32801640
   |texte=   Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32801640" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidSeniorV1

This area was generated with Dilib version V0.6.37.
Data generation: Thu Oct 15 09:49:45 2020. Site generation: Wed Jan 27 17:10:23 2021

	Serveur d'exploration sur la COVID chez les séniors
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID chez les séniors

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki